Leading Authorities on Clinical Trials Present Ways to Avoid the Industry's Biggest Pitfalls

Oct 31, 2006, 00:00 ET from FDAnews

    FALLS CHURCH, Va., Oct. 31 /PRNewswire/ -- The industry's foremost
 authorities on clinical research will lead Clinical Trials: Effective
 Recruitment and Informed Consent Strategies, a 2 day workshop in
 Philadelphia, PA (http://www.fdanews.com/informedconsent), sponsored by the
 RxTrials Institute and FDAnews.
     This interactive workshop focuses on how to speed the IRB and FDA
 review processes, shorten trial cycles and get products to market faster.
 For more information on the workshop, call toll free (888) 838-5578, +1
 (703) 538-7600 or visit http://www.fdanews.com/informedconsent.
     Failure to recruit subjects is the number one reason clinical trials do
 not meet deadlines. Compounded by failure to properly consent patients, 72
 percent of all trials run over schedule by more than one month and only 6
 percent are completed on time. Delayed or canceled studies and negative
 publicity can cost companies millions - even billions - of dollars. This
 hands-on session will address ways to avoid the industry's biggest
     Workshop faculty who will lead this event include:
     Christine Pierre, RN, President and CEO, RxTrials, Inc.
     Mark Hochhauser, Ph.D., Consultant, Member of the Institutional Review
      Board, North Memorial Health Care
     Clint Hermes, Partner, Ropes & Gray LLP
     Linda Strause, Ph.D., Executive Director, Oncology Clinical Operations,
      Vical Inc.
     RxTrials Institute, the foremost expert on clinical research site
 management, marketing, and business development, is pleased to present a
 comprehensive series of training programs for the clinical research team.
 RxTrials Institute is known nationwide for groundbreaking presentations and
 customized training programs that are both innovative and dynamic.
     FDAnews is the premier provider of domestic and international
 regulatory, legislative and business news and information for executives in
 industries regulated by the U.S. Food and Drug Administration.
 Pharmaceutical and medical device professionals rely on FDAnews' print and
 electronic newsletters, books, special reports and conferences to stay in
 compliance with international standards and FDA's complex and ever-changing
 regulations to get their products to market faster and boost profits.